EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HOOKIPA Pharma's enterprise value is $-20.36 Mil.
HOOKIPA Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $9.35 Mil. Therefore, HOOKIPA Pharma's EV-to-Revenue for today is -2.18.
The historical rank and industry rank for HOOKIPA Pharma's EV-to-Revenue or its related term are showing as below:
HOOK'
s EV-to-Revenue Range Over the Past 10 Years
Min: -5.13 Med: 0.3 Max: 78.99
Current: -2.18
During the past 8 years, the highest EV-to-Revenue of HOOKIPA Pharma was 78.99. The lowest was -5.13. And the median was 0.30.
HOOK's EV-to-Revenue is ranked better than 94.99% of 998
companies
in the Biotechnology industry
Industry Median: 7.38
vs HOOK: -2.18
As of today (2025-05-28), HOOKIPA Pharma's stock price is $1.56.
HOOKIPA Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.75. Therefore, HOOKIPA Pharma's PS Ratio for today is 2.09.
HOOKIPA Pharma EV-to-Revenue Historical Data
The historical data trend for HOOKIPA Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HOOKIPA Pharma's EV-to-Revenue
For the Biotechnology subindustry, HOOKIPA Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's EV-to-Revenue falls into.
HOOKIPA Pharma's current Enterprise Value is $-20.36 Mil.
HOOKIPA Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma's share price for today is $1.56.
HOOKIPA Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of HOOKIPA Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HOOK has been successfully added to your 